Recruiting
Acute myeloid leukaemia+1
RecruitingA Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation
Registered drugNo placebo
A Study of Gilteritinib to Eliminate Remaining Cancer Cells in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation
Registered drugNo placebo
- Disease:Acute myeloid leukaemiaFLT3 gene mutation
- Substances:Gilteritinib
Countries:
Greece
Greece- Participants:18–64 years · 65+ years
- Substances:Gilteritinib
- Sponsor:Hellenic Society Of Hematology